Echinacea for Upper Respiratory Infection

,

Original Research

Echinacea for Upper Respiratory Infection

J Fam Pract. 1999 August;48(8):628-635

References

1. Campbell H. Acute respiratory infection: a global challenge. Arch Dis Childhood 1995;73:281-3.

2. Murray CJL, Lopez AD. The global burden of disease. Cambridge, Mass: Harvard University Press, 1996.

3. Oh HM. Upper respiratory tract infections—otitis media, sinusitis and pharyngitis. Singapore Med J 1995;36:428-31.

4. Spector SL. The common cold: current therapy and natural history. J Allergy Clin Immunol 1995;95:1133-8.

5. De Lange de Klerk ESM, Blommers JKDJ, Bezemer PD, Feenstra L. Effects of homeopathic medicines on daily burden of symptoms in children with recurrent upper respiratory tract infections. BMJ 1994;309:1329-32.

6. Fireman P. Pathophysiology and pharmacotherapy of common upper respiratory diseases. Pharmacotherapy 1993;3:101S-9S.

7. Hueston WJ. Albuterol delivered by metered-dose inhaler to treat acute bronchitis. J Fam Pract 1994;39:437-40.

8. McMillan JA. Upper respiratory tract infections in children. Current Opin Pediatr 1993;5:50-4.

9. Monto AS. Viral respiratory infections in the community: epidemiology, agents, and interventions. Am J Med 1995;99:24S-7S.

10. Walker TA, Khurana S, Tilden SJ. Viral respiratory infections. Pediatr Clin North Am 1995;41:1365-81.

11. Dere WH. Acute bronchitis: results of US and European trials of antibiotic therapy. Am J Med 1992;92:53S-7S.

12. Fahey T, Stocks N, Thomas T. Quantitative systematic review of randomized controlled trials comparing antibiotic with placebo for acute cough in adults. BMJ 1998;316:906-10.

13. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory infections, and bronchitis by ambulatory care physicians. JAMA 1997;278:901-4.

14. Mainous AG, III, Hueston WJ, Clark JR. Antibiotics and upper respiratory infection: do some folks think there is a cure for the common cold? J Fam Pract 1996;42:357-61.

15. Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA 1998;279:875-7.

16. Oeffinger KC, Snell LM, Foster BM, Panico KG, Archer RK. Diagnosis of acute bronchitis in adults: a national survey of family physicians. J Fam Pract 1997;45:402-9.

17. Orr PH, Scherer K, Macdonald A, Moffatt MEK. Randomized placebo-controlled trials of antibiotics for acute bronchitis: a critical review of the literature. J Fam Pract 1993;36:507-12.

18. Bergmann KC. Assessment of the clinical value of using an immunomodulator in recurrent respiratory infections. Adv Exp Med Biol 1995;371B:795-7.

19. Riedl-Seifert RJ, van Aubel A, Kammereit A, Elsasser U. Reduction of the number and severity of respiratory tract infections in children by oral immunostimulation. Adv Exp Med Biol 1995;371B:799-802.

20. Foster S. Echinacea: nature’s immune enhancer. Rochester, Vt: Healing Arts Press, 1991.

21. Hobbs C. Echinacea: a literature review. HerbalGram 1994;30(suppl):33-47.

22. Puckner WA. Echinacea considered valueless: report of the council on pharmacy and chemistry. JAMA 1909;1836.-

23. Blumenthal M, Goldberg A, Gruenwald J, et al. German Commission E monographs: therapeutic monographs on medicinal plants for human use. Austin, Tex: American Botanical Council, 1998.

24. Keller K. Legal requirements for the use of phytopharmaceutical drugs in the Federal Republic of Germany. J Ethnopharmacol 1991;32:225-9.

25. Tyler VE. Phytomedicines in Western Europe: their potential impact on herbal medicine in the United States. HerbalGram 1994;30:24-31.

26. Awang DVC, Kindack DG. Herbal medicine: Echinacea. Can Pharma J 1991;124:512-6.

27. Foster S. Echinacea: the purple coneflowers. Austin, Tex: American Botanical Council, 1996.

28. Hobbs C. Echinacea: the immune herb! Santa Cruz, Calif: Botanica Press, 1995.

29. Parnham MJ. Benefit-risk assessment of the squeezed sap of the purple coneflower (Echinacea purpurea) for long-term oral immunostimulation. Phytomedicine 1996;3:95-102.

30. Cohen MH. Complementary and alternative medicine: legal boundaries and regulatory perspectives. Baltimore, Md: Johns Hopkins University Press, 1998.

31. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993;328:246-52.

32. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA 1998;280:1569-75.

33. Landmark Healthcare. The Landmark report on public perceptions of alternative care: 1998 nationwide study of alternative care. Random telephone survey of 1500 households. Sacramento, Calif: Landmark Healthcare, Inc, 1998.

34. Brevoort P. The booming US botanical market: a new overview. HerbalGram 1998;44:33-46.

35. Brevoort P. The US botanical market: an overview. HerbalGram 1996;36:49-57.

36. Bukovsky M, Vaverkova S, Kostalova D. Immunomodulating activity of Echinacea gloriosa L, Echinacea angustifolia DC, and Rudbeckia speciosa Wenderoth ethanol-water extracts. Pol J Pharmacol 1995;47:175-7.

37. Coeugniet EG, Elek E. Immunomodulation with Viscum album and Echinacea purpurea extracts. Onkologie 1987;10 (suppl):27-33.

38. Lersch C, Zeuner M, Bauer A, et al. Stimulation of the immune response in outpatients with hepatocellular carcinomas by low doses of cyclophosphamide (LDCY), Echinacea purpurea extracts (Echinacin) and thymostimulin. Arch Geschwulstforsch 1990;60:379-83.

39. Lersch C, Zeuner M, Bauer A, et al. Nonspecific immunomodulation with low doses of cyclophosphamide (LDCY), thymostimulin, and Echinacea purpurea extracts (Echinacin) in patients with far advanced colorectal cancers. Cancer Invest 1992;10:343-8.

40. Luettig B, Steinmuller C, Gifford GE, Wagner H, Lohman-Matthes ML. Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea. J Natl Cancer Inst 1989;

41. Melchart D, Linde K, Worku F, et al. Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea. J Altern Complement Med 1995;1:145-60.

42. Stimpel M. Macrophage activation and induction of macrophage cytotoxicity by purified polysaccharide fractions from the plant Echinacea purpurea. Infect Immun 1984;46:845-9.

43. Bauer R, Wagner H. Echinacea species as potential immunostimulatory drugs. In: Wagner H, Farnsworth NR, eds. Economic and medicinal plant research. New York, NY: Academic Press Limited, 1991.

44. Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG. Echinacea-induced cytokine production by human macrophages. Int J Immunopharmacol 1997;19:371-9.

45. Elsasser-Beile U, Willenbacher W, Bartsch HH, Gallati H, Schulte Monting J, von Kleist S. Cytokine production in leukocyte cultures during therapy with Echinacea extract. J Clin Lab Anal 1996;10:441-5.

46. Roesler J, Steinmuller C, Kiderlen A, Emmendorffer A, Wagner H, Lohmann ML. Application of purified polysaccharides from cell cultures of the plant Echinacea purpurea to mice mediates protection against systemic infections with Listeria monocytogenes and Candida albicans. Int J Immunopharmacol 1991;13:27-37.

47. Steinmuller C, Roesler J, Grottrup E, Franke G, Wagner H, Lohmann-Matth M. Polysaccharides isolated from plant cell cultures of Echinacea purpurea enhance the resistance of immunosuppressed mice against systemic infections with Candida albicans and Listeria. Int J Immunopharmacol 1993;15:605-14.

48. Tragni E. Evidence from two classic irritation tests for an anti-inflammatory action of a natural extract, Echinacea. Food Chem Toxicol 1985;23:317-9.

49. Tragni E, Galli CL, Tubaro A, del Negro P, Della Loggia R. Anti-inflammatory activity of Echinacea angustifolia fractions separated on the basis of molecular weight. Pharmaceut Res Comm 1998;20(suppl):87-91.

50. Tubaro A, Tragni E, del Negro P, Galli CL, Della Loggia R. Anti-inflammatory activity of a polysaccharide fraction of Echinacea angustifolia. J Pharm Pharmacol 1987;39:567-9.

51. Wacker A. Virus inhibition by Echinacea purpurea. Planta Medica 1978;33:89-102.

52. Bauer R. Echinacea: biological effects and active principles. In: Lawson LD, Bauer R, eds. Phytomedicines of Europe: chemistry and biological activity. Washington, DC: American Chemists Society 1998;140-157.

53. Bone K. Echinacea: what makes it work? Altern Med Rev 1997;2:87-9.

54. Melchart D, Linde K, Worku F, Bauer R, Wagner H. Immunomodulation with Echinacea: a systematic review of controlled trials. Phytomedicine 1994;1:245-54.

55. Bräunig B, Dorn M, Limburg E, Knick E. Bausendorf: Echinaceae purpureae radix: zur Stärkung der körpereigenen Abwehr bei grippalen Infekten. Zeitschrift fur Phytotherapie 1992;13:7-13.

56. Bräunig B, Knick E. Therapeutische Erfahrungen mit Echinaceae pallidae bei grippalen Infekten. Naturheilpraxis 1993;1:72-5.

57. Dorn M. Milerung grippaler Effeckte durch ein pflanzliches Immunstimulans. Nutur Ganzheitsmedizin 1989;2:314-9.

58. Forth H, Beuscher N. Beeinflussing der Häufigkeit banaler Erkältungsinfekte durch Esberitox. Zeitschrift für Allgemeinmedizin 1981;57:2272-5.

59. Reitz HD. Immunmodulatoren mit pflanzlichen Wirkstoffen: eine wissenschaftliche Studie am Beispiel Esberitox N. Notabene medici 1990;20:362-6.

60. Schmidt U, Albrecht M, Schenk N. Pflankliches Immunstimulans senkt Häufigkeit grippaler Infekte: Plazebokontrollierte Doppelblindstudie mit einem kombinierten Echinacea-Präparat mit 646 Studenten der Kölner Universität. Natur Ganzheits Medizin 1990;3:277-81.

61. Schöneberger D. Einfluß der immunstimulierenden Wirkung von Preßsaft aus Herba Echinaceae purpureae auf Verlauf und Schweregrad von Erkältungskrankheiten. Ergebnisse einer Doppelblindstudie. Forum Immunologie 1992;2:18-22.

62. Vorberg G. Bei Erkältung unspezifische Immunabwehr stimulieran: Doppelblindstudie zeigt: Das bewährte Phytotherapeutikum Esberitox verkürzt die Symptommatik. Ärztliche Praxis 1984;36:97-8.

63. Vorberg G, Schneider B. Pflanzliches Immunstimulans verkürzt grippalen Infeckt. Doppelblindstudie belegt die Steigerung der unspezifischen Infektabwehr. Ärztliche Forschung 1989;36:3-8.

64. Galea S, Thacker K. Double-blind prospective trial investigating the effectiveness of a commonly prescribed herbal remedy in altering the duration, severity and symptoms of the common cold. Unpublished manuscript, 1996.

65. Grimm W, Muller HH. A randomized controlled trail of the effect of fluid extract of Echinacea purpurea on incidence and severity of colds and respiratory infections. Am J Med 1999;106:138-144.

66. Brinkeborn R, Shah D, Geissbühler S, Degenring FH. Echinaforce in the treatment of acute colds. Schweiz Zschr GanzheitsMedizin 1998;10:26-9.

67. Hoheisel O, Sandberg M, Bertram S, Bulitta M, Schäfer M. Echinagard treatment shortens the course of the common cold: a double-blind, placebo-controlled clinical trial. Eur J Clin Res 1997;9:261-8.

68. Melchart D, Walther E, Linde K, Brandmaier R, Lersch C. Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial. Arch Fam Med 1998;7:541-5.

69. Mengs U, Clare CB, Poiley JA. Toxicity of Echinacea pur

70. Mullins RJ. Echinacea-associated anaphylaxis Med J Aust 1998;168:170-1.

71. Reichling J, Saller R. Control in the manufacturing of modern herbal remedies. Q Rev Nat Med 1998;Spring:21-8.

There is currently no universally accepted standardization procedure to ensure comparability among products. Unfortunately, given the apparent multiple chemical nature of Echinacea’s mode of action and the unequal distribution of active constituents in the flowers, leaves, stems, and roots of the 3 medicinal species, it is difficult to determine exactly what kind of standardization would be optimal.⁷¹ As there are a number of substances and mechanisms underlying Echinacea’s observed clinical effects, it seems possible that whole-extract dosing might indeed remain preferable to isolation and purification of single chemical entities. Still, as the concentrations of active ingredients are known to vary by species, among roots, leaves, and flowers, and most likely by season, soil type, and climate, and as there is very little research that tests one formulation against another, no recommendations regarding specific Echinacea products can be made.

Recommendations for clinical practice

The use of Echinacea for the early treatment of the common cold can be cautiously supported. More evidence is needed before clear recommendations can be made regarding specific formulations or dosing. Extracts from E purpurea, E angustifolia, and E pallida roots, leaves, and flowers cannot at this point be distinguished from each other in terms of their apparent beneficial activity. If the decision is made to use an Echinacea product, we recommend that it be taken early in the course of a cold, several times per day, and discontinued as symptoms abate. We recommend that Echinacea not be taken routinely, chronically, or on a preventive basis. We note that no trials have included infants, children, or pregnant women, and recommend caution among those populations. We also note the theoretical contraindication among persons suffering from serious autoimmune disorders.

At the present time we conclude that the evidence suggests Echinacea taken early in the course of an illness may be safe and effective in reducing the severity and duration of the common cold. The evidence of Echinacea’s ability to prevent infection is inadequate to make any recommendations in this regard.